Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action

International Journal of Clinical Practice, Supplement

Volumn , Issue 127, 2002, Pages 6-19

  Poirier, J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Butyrylcholinesterase; Donepezil; Galantamine; Potency; Rivastigmine; Tacrine; Targeted efficacy

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; RIVASTIGMINE; TACRINE;

ALLOSTERISM; ALZHEIMER DISEASE; BRAIN REGION; CEREBROSPINAL FLUID; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LEWY BODY; MULTIINFARCT DEMENTIA; NAUSEA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VOMITING;

CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; NOOTROPIC AGENTS;

EID: 0036065671     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Selective loss of central cholinergic neurons in Alzheimer's disease
2. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain
3. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse
4. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase
5. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease
6. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease
7. Butyrylcholinesterase K variant and Alzheimer's disease
8. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland
9. Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains
10. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K)
11. Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease
12. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition
13. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase
14. Selectivity of cholinesterase inhibition
15. Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology
16. Neuroanatomy of Alzheimer's disease
17. Cholinergic systems in the human brain: Psychopharmacology and psychosis
18. Remote memory function in Alzheimer's disease and Parkinson's disease
19. What is vascular dementia?
20. Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation
21. Changes in brain cholinesterases in senile dementia of Alzheimer type
22. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia
23. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine
24. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
25. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy
26. Butyrylcholinesterase in the life cycle of amyloid plaques
27. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme
28. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - A study of molecular forms
29. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease
30. Longterm tacrine (Cognex) treatment: Effects on nursing home placement and mortality
31. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans
32. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment
33. Dosedependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
34. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain
35. Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice
36. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
37. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses
38. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex
39. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
40. Longterm tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG and cognitive abilities
41. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit
42. Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1 year: Differential effects across time
43. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine
44. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain
45. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients
46. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease
47. Improved cortical glucose metabolism in Alzheimer's disease (AD) patients treated with rivastigmine for 1 year
48. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation
49. Changes in the rCBF images of patients with Alzheimer's disease receiving donepezil therapy
50. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
51. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR
52. Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors
53. Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia
54. Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications
55. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography
56. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment
57. Evaluation of pharmacotherapeutic interventions in AD - Role of PET studies
58. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
59. Apolipoprotein E polymorphism and Alzheimer's disease
60. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
61. A randomized trial evaluating the efficacy and safety of ENA-713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
62. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?
63. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
64. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
65. Galantamine in AD, a 6-month randomized placebo-controlled trial with a 6-month extension
66. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double blind, placebo-controlled international study
67. Rivastigmine in the treatment of parkinsonian hallucinosis
68. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
69. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia
70. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease
71. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
72. Donepezil improves cognition and global function in Alzheimer disease
73. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
74. A randomized double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
75. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
76. A 5-month, randomised, placebo-controlled trial of galantamine in AD
77. Advantages in long-term treatment with Cognex in Alzheimer disease
78. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
79. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease
80. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease
81. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
82. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease
83. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial
84. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
85. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease
86. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial
87. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
88. An efficacy and safety analysis of Exelon in Alzheimer's disease with concurrent vascular risk factors
89. Treatment of symptoms specific to patients with subcortical vascular dementia: An open label pilot study comparing rivastigmine and cardioaspirin
90. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial
91. Results of clinical studies with donepezil in vascular dementia